Security Snapshot

NEUROCRINE BIOSCIENCES INC - Common Stock, $0.001 par value (NBIX) Institutional Ownership

CUSIP: 64125C109

13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

778

Shares (Excl. Options)

100.97MFull value: 100,965,712 · shares · 30 Jun 2026

Price

$168.54

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock, $0.001 par value
Symbol
NBIX on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
100,965,712
Latest holder snapshot 5 signals
Total 13F value
$17,003,291,455
Portfolio coverage rank
0.01%
Share change
+836,203
Value change
+$207,130,939
Number of holders
778
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
101,930,577
SEC-reported price per share
$141.84
Insider filing price
$141.84
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock, $0.001 par value is tracked under CUSIP 64125C109.
  • 778 institutions reported positions in Q2 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 701 to 778 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $13.18BFull value: $13,175,633,880 · USD · 31 Mar 2026
    to
    $17BFull value: $17,003,291,455 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 778 institutions filings for Q2 2026.

Open SEC evidence

Security key

64125C109

13F reference period

Q2 2026

13F holders

778

13D/G owners

5

CIK / CUSIP context first

Open Q2 2026 holders NBIX full holder history NEUROCRINE BIOSCIENCES INC SEC filings NEUROCRINE BIOSCIENCES INC company facts NEUROCRINE BIOSCIENCES INC insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
5
Security
NBIX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 12% $1,274,648,181 12,052,271 BlackRock, Inc. 31 Mar 2025
DODGE & COX 5.6% $585,341,834 5,534,624 Dodge & Cox 31 Mar 2025
JPMORGAN CHASE & CO 5.2% -18% $751,807,318 -$147,208,644 5,300,390 -16% JPMORGAN CHASE & CO. 30 Sep 2026
VANGUARD CAPITAL MANAGEMENT LLC 5.2% $692,681,147 5,257,941 Vanguard Capital Management 31 Mar 2026
STATE STREET CORP 4.8% $517,286,649 4,891,137 STATE STREET CORPORATION 31 Dec 2024
As of 30 Jun 2026, 778 institutional investors reported holding
100.97MFull value: 100,965,712 · shares · 30 Jun 2026
shares of NEUROCRINE BIOSCIENCES INC - Common Stock, $0.001 par value (NBIX). This represents 99% of the company’s total
101.93MFull value: 101,930,577 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
64%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 13% 13,711,607 +2.4% 0.03% $2,310,885,707
JPMORGAN CHASE & CO 6.3% 6,398,674 +18% 0.06% $1,088,569,109
Dodge & Cox 5.5% 5,584,707 +2.3% 0.49% $941,218,594
VANGUARD PORTFOLIO MANAGEMENT LLC 4.9% 4,974,083 +5.2% 0.04% $838,307,078
VANGUARD CAPITAL MANAGEMENT LLC 4.5% 4,545,339 +0.74% 0.02% $766,048,708
STATE STREET CORP 4.3% 4,385,598 +0.71% 0.02% $739,126,759
AQR CAPITAL MANAGEMENT LLC 3.7% 3,818,037 -23% 0.22% $643,472,716
RENAISSANCE TECHNOLOGIES LLC 2.3% 2,335,897 -3.4% 0.54% $393,680,402
GEODE CAPITAL MANAGEMENT, LLC 2.1% 2,138,777 +0.1% 0.02% $359,607,676
TWO SIGMA INVESTMENTS, LP 2% 2,076,260 -32% 0.26% $349,922,479
Vestal Point Capital, LP 1.8% 1,880,000 +50% 7.4% $316,845,800
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.5% 1,494,259 +0.03% 0.25% $251,858,951
MORGAN STANLEY 1.3% 1,318,607 +8.2% 0.01% $222,231,858
RTW INVESTMENTS, LP 1.2% 1,267,925 +19% 1.8% $213,689,740
NORTHERN TRUST CORP 1.2% 1,259,717 +1.4% 0.02% $212,306,405
Invesco Ltd. 1.1% 1,077,317 +203% 0.01% $181,565,621
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.96% 974,279 +7.9% 0.02% $164,200,136
NORGES BANK 0.96% 973,880 0.02% $164,132,866
FIRST TRUST ADVISORS LP 0.91% 923,125 -3.8% 0.09% $155,578,851
DIMENSIONAL FUND ADVISORS LP 0.72% 732,877 +3% 0.02% $123,525,529
JACOBS LEVY EQUITY MANAGEMENT, INC 0.71% 726,112 +40% 0.44% $122,375,286
Bank of New York Mellon Corp 0.69% 699,125 -0.48% 0.02% $117,826,993
Swedbank AB 0.64% 651,082 +12% 0.09% $109,730,107
VANGUARD FIDUCIARY TRUST CO 0.64% 647,763 +2.1% 0.02% $109,170,737
IEQ CAPITAL, LLC 0.63% 640,304 -16% 0.5% $107,913,614

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
51
Headline period
Q2 2026
Rows shown
1-25 of 51
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 3,570,519 $505,275,246 +$125,924,143 $141.84 187
2026 Q2 100,965,712 $17,003,291,455 +$207,130,939 $168.54 778
2026 Q1 100,159,474 $13,175,633,880 +$7,733,801 $131.74 701
2025 Q4 99,172,264 $14,056,573,274 +$307,271,827 $141.83 728
2025 Q3 96,958,838 $13,606,200,694 -$264,723,748 $140.38 642
2025 Q2 98,821,219 $12,420,453,326 +$494,184,481 $125.69 578
2025 Q1 95,485,987 $10,559,467,994 +$7,244,935 $110.60 579
2024 Q4 94,376,685 $12,879,887,685 +$230,192,847 $136.50 596
2024 Q3 93,003,458 $10,720,376,398 -$150,384,737 $115.22 570
2024 Q2 93,636,708 $12,887,512,754 +$47,493,212 $137.67 589
2024 Q1 93,218,731 $12,853,312,563 +$116,424,918 $137.92 580
2023 Q4 92,326,586 $12,160,216,767 +$5,244,067 $131.76 545
2023 Q3 92,001,152 $10,350,228,156 +$38,916,412 $112.50 508
2023 Q2 91,514,317 $8,634,655,568 +$37,920,952 $94.30 452
2023 Q1 90,892,702 $9,194,138,307 +$67,286,199 $101.22 481
2022 Q4 90,124,434 $10,754,797,482 +$104,201,709 $119.44 525
2022 Q3 90,489,863 $9,610,613,890 -$33,115,379 $106.21 451
2022 Q2 89,687,591 $8,740,480,340 -$27,492,643 $97.48 426
2022 Q1 90,130,456 $8,447,849,857 +$146,450,381 $93.75 413
2021 Q4 89,152,258 $7,586,914,975 -$142,540,543 $85.17 389
2021 Q3 90,241,905 $8,655,761,280 -$94,927,615 $95.91 390
2021 Q2 91,390,637 $8,892,923,286 -$379,127,377 $97.32 398
2021 Q1 95,118,085 $9,245,217,222 +$547,907,714 $97.25 410
2020 Q4 89,436,431 $8,572,935,331 -$29,252,870 $95.85 394
2020 Q3 89,711,420 $8,625,616,767 -$165,135,029 $96.16 410
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .